ScienTek accelerates aptamer discovery for challenging protein targets using an AI-powered platform. Their technology combines in silico screening with in vitro validation to identify and optimize nucleic acid sequences with high binding affinity for next-generation therapeutics.
Funding
Funding not disclosed
Founders
Product
Problem
Developing novel aptamer therapeutics for challenging protein targets requires extensive screening and optimization, which can be time-consuming and resource-intensive. Traditional methods often struggle to achieve the high binding affinity and specificity necessary for effective therapeutic applications.
Solution
ScienTek offers an AI-powered platform designed to accelerate aptamer discovery and development for next-generation therapeutics. The platform facilitates the identification and optimization of novel nucleic acid sequences capable of targeting difficult proteins with nanomolar binding affinity. By integrating in silico screening of trillions of potential nucleic acid-protein interactions with in vitro laboratory validation, ScienTek streamlines the process from initial design to lead optimization. This approach enables the creation of precisely engineered aptamer molecules for targeted drug delivery and therapeutic interventions.
Target Audience
ScienTek serves biotechnology and pharmaceutical companies engaged in the development of novel therapeutics, particularly those targeting complex or previously undruggable protein targets.
Features
- AI-driven in silico screening of up to trillions of nucleic acid-protein interactions to identify potential drug candidates.
- In vitro validation utilizing spectroscopy, anisotropy, and Surface Plasmon Resonance (SPR) to assess binding affinity and specificity.
- Enzyme-linked aptamer assays (ELAA) and fluorescence-based binding studies for confirming target interactions.
- Proprietary computational pipelines and AI technologies for rational aptamer design and property prediction, including folding behavior.
- Optimization of lead compounds through chemical modifications to enhance pharmacokinetic properties.
- Generation of highly specific aptamers tailored to target molecules using advanced computational methods.
- Focus on developing aptamers for targeting "undruggable" proteins.